First, revenue growth was a measly 2%. There's no way to get excited about that. Sure, cost cutting led to a 4% increase in adjusted operating income, but it's the future that counts for Lilly.
As outlined here -- go ahead and read, I'll wait -- Eli Lilly is facing generic competition for many of its top drugs over the next few years. Rather than focusing on quarterly earnings, investors are worried about the pipeline, which doesn't look too solid.
Earlier this week, the company announced that an approval on Bydureon, which is partnered with Amylin Pharmaceuticals
What's Eli Lilly to do? Press on, of course. Its pipeline isn't completely empty, but I don't see how it can get through this mess without a concerted effort to add drugs through licensing or acquisitions. Fortunately, the cost-cutting measures will contribute to the cash hoard, which stood at $5.2 billion at the end of the second quarter.
Eli Lilly now trades at about 7.5 times this year's adjusted earnings guidance and sports a dividend yield of 5.5%. That looks cheap, even considering that its peers -- Pfizer
No amount of cost cutting is going to cause the P/E multiple to expand. That'll only occur after the patent cliff or when investors are convinced that the pipeline can put a dent in the coming revenue decline.
Interested in keeping track of Lilly as it navigates the patent cliff? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Lilly.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.